Close Menu

Agilent Technologies: Mark Doak, Padriag McDonnell

Jan 23, 2020

Agilent Technologies said this week that Mark Doak will retire as senior VP of the firm and president of Agilent CrossLab Group, effective May 1, 2020. Agilent has named Padraig McDonnell, currently VP and general manager of the firm's chemistries and supplies division, to succeed Doak. McDonnell has served in various roles at Agilent for 22 years.  

More Like This

Apr 15, 2021

Inflammatix: Amy Boyle

Inflammatix has appointed Amy Boyle as its chief operating officer. Boyle has 30 years of commercial medical device experience, with expertise in strategy, market development, sales and marketing, commercial operations, and manufacturing.

Most recently, she served as vice president, strategy, planning, and marketing for the health solutions division of Flex. Prior to that, she was vice president, marketing for the urology division of Coloplast, where she led global expansion and growth of the surgical urology business, and launched the firm's endourology portfolio in the US.

Previously, Boyle was executive vice president of marketing for Imris and spent five years at St. Jude Medical, first as vice president, marketing, international, responsible for cardiovascular businesses, and then as vice president, corporate brand and marketing. She also spent 17 years with Medtronic in Canada and the US in a variety of sales roles, including regional vice president of sales for the cardiac rhythm management business.

Apr 15, 2021

Ancestry: Gene Alston

Consumer genomics firm Ancestry has appointed Gene Alston as an independent member of its board of directors. Alston is currently vice president of commerce business and operations at Facebook. Prior to this, he held various positions at Pinterest, Groupon, and PayPal, where he led teams and was responsible for business development, partnerships, acquisitions, and international expansion.

Apr 15, 2021

InterVenn Biosciences: James Allison, Padmanee Sharma

InterVenn Biosciences, a company specializing in glycoproteomics for precision medicine applications, has appointed James Allison and Padmanee Sharma to its advisory board.

Allison is chair of the Department of Immunology, chair for cancer research, director of the Parker Institute for Cancer Research, and executive director of the immunotherapy program at MD Anderson Cancer Center. In 2018 Allison was awarded the Nobel Prize in Physiology or Medicine for discovery of a new way to treat cancer by leveraging the body's immune system to attack the tumor.

Sharma is professor in the Departments of Genitourinary Medical Oncology and Immunology and chair in cell biology in the Cancer Medicine Division at MD Anderson Cancer Center. Her translational research focuses on learning how to apply immune-based therapeutic strategies to manipulate components of the human immune system to lead to tumor regression.

Apr 15, 2021

Specific Diagnostics: Scott Wehage

Specific Diagnostics has appointed Scott Wehage the company's director of US clinical trials. He was previously clinical project manager for Becton Dickinson's global clinical development department and oversaw clinical trials for device and in vitro diagnostic product development. Prior to that, he was a program manager at Johns Hopkins University. Based in Mountain View, California, Specific Dx has developed an IVD system leveraging a metabolomic signature technology that allows for the detection and identification of microorganisms as they grow in culture. The first commercial application of the technology will be for the determination of antibiotic susceptibility.

Apr 13, 2021

Sera Prognostics: Benjamin Jackson

Benjamin Jackson has been appointed as general counsel of Sera Prognostics. He joins the Salt Lake City-based pregnancy health company from Myriad Genetics, where he held the same position.

Apr 13, 2021

Macrogen Europe: Bongcho Kim

Sequencing services provider Macrogen Europe has appointed Bongcho Kim as CEO. He has been tasked with expanding the company's sequencing and bioinformatics capabilities.

Kim was previously director of technology and innovation of Seoul-based Macrogen. He joined the firm in 2013 as general manager for next-generations sequencing overseas sales before being promoted to director and VP.

Kim holds a doctorate in pathology from Seoul National University.

Apr 12, 2021

ACMG: Susan Klugman, Shweta Dhar, Hutton Kearney, David Stevenson, Jerry Vockley

The American College of Medical Genetics and Genomics has added five new members to its board of directors, including its new president-elect. They will serve six-year terms starting this month.

Susan Klugman is ACMG's president-elect. She is the director of the division of reproductive and medical genetics at Albert Einstein College of Medicine and Montefiore Medical Center. Klugman holds an a bachelor of science in biometry and statistics from Cornell University and an MD from New York University School of Medicine. She is board certified in clinical genetics and in obstetrics and gynecology.

Shweta Dhar is an associate professor in the department of molecular and human genetics and the department of internal medicine at Baylor College of Medicine. She is a graduate of Nathiba Hargovandas Lakhmichand Municipal Medical College in India and holds an MS in biotechnology from Stephen F. Austin State University in Texas. She is board certified in clinical genetics and internal medicine.

Hutton Kearney is vice chair of hereditary genomics in the Mayo Clinic Division of Laboratory Genetics and Genomics and an assistant professor of laboratory medicine and pathology. She holds a BS in secondary education from Auburn University and a PhD in genetics and molecular biology from the University of North Carolina at Chapel Hill. She is board certified in clinical cytogenetics and clinical molecular genetics.

David Stevenson is a professor of pediatrics in the division of medical genetics at Stanford University. He holds a BA in biology from Utah State University and an MD from the University of Utah.

Jerry Vockley is chief of the division of medical genetics and director of the Center for Rare Disease Therapy at UPMC Children's Hospital of Pittsburgh. He holds an undergraduate degree from Carnegie Mellon University as well as an MD and a PhD in genetics from the University of Pennsylvania School of Medicine. He is board certified in clinical genetics and in clinical biochemical/molecular genetics.

Apr 12, 2021

Castle Biosciences: Kristen Oelschlager

Castle Biosciences has appointed Kristen Oelschlager as chief operating officer. Oelschlager had been serving as the company's chief operations officer since August 2020. Prior to that, she served as senior vice president of clinical operations from January 2018 to August 2020, VP of clinical operations from 2013 to 2018, and executive director of operations from October 2008 to 2013.
Oelschlager also served as director of clinical research for Arizona Pulmonary Specialists from May 1996 to September 2008.
Apr 12, 2021

Genetic Technologies: Michael Tonroe

Michael Tonroe has been appointed as CFO of Australian molecular diagnostics company Genetic Technologies, effective June 28. Previously, he was CFO and company secretary at Opthea, and before that, CFO and company secretary at the Australian Synchrotron. Tonroe holds a graduate degree in business studies from Buckingham University in the UK.

Apr 09, 2021

Micronoma: Jennifer Wargo

Micronoma, a company using signals from the tumor-related microbiome for liquid biopsy-based cancer diagnosis, has appointed Jennifer Wargo to its scientific advisory board. Wargo is a professor of surgical oncology and genomic medicine at the University of Texas MD Anderson Cancer Center.

Apr 08, 2021

Mission Bio: Yan Zhang, Charlie Silver

Single-cell analysis firm Mission Bio has appointed Yan Zhang as CEO.

Zhang joins Mission Bio after 10 years at Thermo Fisher Scientific, where she led that firm's commercial organization in China for genetic sciences and clinical next-generation sequencing and was general manager for its reproductive health and microarray businesses. Prior to Thermo, Zhang held product management and commercialization roles at Affymetrix, NuGen Technologies, and Molecular Devices. She holds a PhD in biochemistry from the Medical College of Wisconsin.

Former CEO Charlie Silver, a Mission Bio cofounder, will move into an advisory role.

Apr 06, 2021

Nautilus Biotechnology: Matt Murphy

Nautilus Biotechnology has appointed Matt Murphy as general counsel.

Murphy brings more than 25 years of experience as senior legal counsel for life sciences companies. He was previously VP and general counsel for both 10x Genomics and Pacific Biosciences and has advised companies including Caliper Technologies, BioElectron Technology, and Nanosys.

Murphy holds a law degree from the University of San Francisco.

Apr 06, 2021

NRGene: Keith Blanks, Richard Calk

NRGene has hired Keith Blanks as chief commercial officer and Richard Calk as chief strategy officer. Blanks previously was senior VP of sales and marketing at Calyxt, where he led the launch of one of the world's first gene-edited food products. Calk joins NRGene after serving as president and COO of Neogen. NRGene said that the two will help the Israeli company grow in North America.

Apr 05, 2021

Quadrant Biosciences: Brady Millican

Quadrant Biosciences announced Brady Millican has joined the firm as executive VP of sales. He has more than 30 years of experience in sales, marketing, business development, and operations in the medical diagnostics and prognostics space and was most recently chief business officer of Admera Health. Before that, he had senior level sales and marketing positions at Bostwick, Ameripath, and Dianon Laboratories. Based in Syracuse, New York, Quadrant has developed Clarifi ASD, a molecular saliva-based test for autism spectrum disorder, as well as Clarifi COVID-19, a saliva-based test codeveloped with the SUNY Upstate Medical University, which received Emergency Use Authorization from the US Food and Drug Administration in September.

Apr 05, 2021

Akoya Biosciences: Frederick Pla

Akoya Biosciences has appointed Frederic Pla as its chief operating officer. Pla most recently served as chief operating officer at the Parker Institute for Cancer Immunotherapy. Prior to this, Pla served as COO at Genomic Health before its acquisition by Exact Sciences in 2019. He has also served in leadership positions at Life Technologies, GE Healthcare, and NASA.

NPR reports that researchers have developed chimeric embryos as part of work toward growing human organs in animals for organ transplants.

According to the Washington Post, the Biden Administration is set to make changes to federal restrictions on fetal tissue research.

In Science this week: approach to isolated trace DNA from archaic humans from sediments, and more.

Texas Monthly looks into the DNA Zoo being collected by Baylor College of Medicine researchers.